Higher radiation doses for repeated ventricular tachycardia, a dangerous fast heartbeat
Tests higher radiation doses to the heart in adults with recurrent ventricular tachycardia.
Key facts
- Who runs it
- University of Zurich
- Where
- Bern and Zurich, SwitzerlandSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Started
- 1 Jul 2022
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)
- Record updated
- 21 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with structural heart disease and repeated ventricular tachycardia (a fast, dangerous heart rhythm). They get higher-dose targeted radiation to the heart.
- Age
- 18 years and older.
- Sex
- All sexes can join.
- Disease stage
- Structural heart disease, such as ischemic or non-ischemic cardiomyopathy. Sustained monomorphic VT that keeps coming back. People must have an implanted ICD and/or CRT-D (a device that shocks the heart).
- Earlier treatment
- At least 1 failed catheter ablation for VT, or ablation is not possible. VT came back after ablation despite optimised antiarrhythmic medicine.
Main reasons for not taking part
- Only premature ventricular contractions (extra heartbeats)
- Acute heart attack, or an inherited electrical heart disease (channelopathy)
- VT with a reversible cause, such as drugs or poisoning, that can be treated another way
- Target area cannot be safely defined for radiation, for example due to prior chest radiation
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients with structural heart disease, in particular ischemic and non-ischemic cardiomyopathy: Implanted ICD and/or CRT-D. Prior ≥1 failed catheter ablation (with endocardial ± epicardial approach based on the substrate location and the ECG morphology of clinical VTs) procedure to control sustained monomorphic VT using currently recommended mapping and ablation techniques,2 or patients in whom ablation is not feasible. Reasons for lack of epicardial ablation and non-feasibility of catheter ablation must be specified. Sustained VT recurrence after catheter ablation on optimised antiarrhythmic medication
- Age ≥18 years. IRB-approved, written informed consent must be provided
Who cannot take part
- Acute myocardial infarction; Primary electrical disease (channelopathy); Reversible and treatable cause (e.g., drug-induced or intoxication) of VT that can be adequately addressed otherwise; A target that cannot be safely and precisely defined based on stereotactic radiotherapy accuracy requirements (e.g., anatomical interference from OARs, overlapping prior radiation therapy to the thoracic region); Pregnancy or breastfeeding; Inability to provide informed consent
- Patients with only premature ventricular contractions
- Patients with sustained VT/VF who demonstrate:
Where in Switzerland
Also in 1 other country, 1 site
- Inselspital BernBern, SwitzerlandContact: Boldizsár Kovács, Dr. med.Taking people
- University Hospital ZurichZurich, SwitzerlandContact: Michael Mayinger, MDTaking people
About the trial
What the trial wants to find out
The objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of VT treatment and therefore dose-escalation will lead to a significantly reduced long-term VT recurrence rate compared to the currently applied single dose of 25 Gy.
The group in the trial
- Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)Treatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Dose Escalation for Stereotactic Cardiac Radiation Therapy of Recurrent Ventricular Tachyarrhythmia - a Multi Center, Phase II Clinical Trial
- Plain-language title
- Higher radiation doses for repeated ventricular tachycardia, a dangerous fast heartbeatGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Dose escalation for stereotactic arrhythmia radioablation of recurrent ventricular tachyarrhythmia - a phase II clinical trial.Radiation oncology (London, England), 2023
- Record updated
- 21 August 2026